Session I

Hodgkin Lymphoma

Signaling pathways and immune evasion mechanisms in HL
A. Diepstra
Lecture:

Improved biological insight and new agents in marginal zone lymphomas
C. Thieblemont
Session II

DLBCL

Genomics
R. Dalla Favera
Frontline treatments in DLBCL: what have we learned from the recent trials?
G.S. Nowakowski
New therapies for relapse/refractory DLBCL
S.M. Ansell
The newer: bispecifics
M. Hutchings
Update on CAR-T cells

ZUMA-1 study
S.S. Neelapu
Session III

T-Cell Lymphoma

Are we ready to think about PTCL subtype specific therapy?
R. Advani
New agents in PTCL
R. Advani
And now...CAR-T
M.A. Pule
Session IV

Other Aggressive Entities

Refractory and relapsed primary central nervous system lymphoma
C. Soussain
Session V

Follicular Lymphoma

Current role of epigenetic changes in follicular lymphoma
A.M. Melnick
Are we ready for a risk-adapted approach?
N.H. Fowler
Relapsed/refractory setting: novel agents and approches:

Chemo-free approach
N.H. Fowler
Bispecifics
M. Hutchings
Privacy Policy | Cookie Policy